Detalhe da pesquisa
1.
Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA.
Blood
; 139(6): 835-844, 2022 02 10.
Artigo
Inglês
| MEDLINE | ID: mdl-34289038
2.
Plain language summary of the MAIA study of daratumumab plus lenalidomide and dexamethasone for the treatment of people with newly diagnosed multiple myeloma.
Future Oncol
; 19(13): 887-895, 2023 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-37212642
3.
Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma.
N Engl J Med
; 380(22): 2104-2115, 2019 05 30.
Artigo
Inglês
| MEDLINE | ID: mdl-31141632
4.
Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial.
Lancet Oncol
; 22(11): 1582-1596, 2021 11.
Artigo
Inglês
| MEDLINE | ID: mdl-34655533
5.
Melflufen plus dexamethasone in relapsed/refractory multiple myeloma: long-term survival follow-up from the Phase II study O-12-M1.
Br J Haematol
; 193(6): 1105-1109, 2021 06.
Artigo
Inglês
| MEDLINE | ID: mdl-33403663
6.
Health-related quality of life in patients with relapsed or refractory multiple myeloma: treatment with daratumumab, lenalidomide, and dexamethasone in the phase 3 POLLUX trial.
Br J Haematol
; 194(1): 132-139, 2021 07.
Artigo
Inglês
| MEDLINE | ID: mdl-33822368
7.
Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma.
Blood
; 134(8): 668-677, 2019 08 22.
Artigo
Inglês
| MEDLINE | ID: mdl-31270103
8.
Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma: Part 2 of the open-label, multicenter, dose-escalation phase 1b study (PAVO).
Haematologica
; 106(6): 1725-1732, 2021 06 01.
Artigo
Inglês
| MEDLINE | ID: mdl-32354874
9.
Clinically-suspected cast nephropathy: A retrospective, national, real-world study.
Am J Hematol
; 95(11): 1352-1360, 2020 11.
Artigo
Inglês
| MEDLINE | ID: mdl-32777108
10.
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
N Engl J Med
; 375(14): 1319-1331, 2016 10 06.
Artigo
Inglês
| MEDLINE | ID: mdl-27705267
11.
High-Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action.
Cytometry A
; 95(3): 279-289, 2019 03.
Artigo
Inglês
| MEDLINE | ID: mdl-30536810
12.
Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma.
N Engl J Med
; 373(13): 1207-19, 2015 Sep 24.
Artigo
Inglês
| MEDLINE | ID: mdl-26308596
13.
Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma.
Blood
; 127(6): 681-95, 2016 Feb 11.
Artigo
Inglês
| MEDLINE | ID: mdl-26631114
14.
Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma.
Blood
; 128(1): 37-44, 2016 07 07.
Artigo
Inglês
| MEDLINE | ID: mdl-27216216
15.
Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma.
Blood
; 128(3): 384-94, 2016 07 21.
Artigo
Inglês
| MEDLINE | ID: mdl-27222480
16.
Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma.
Blood
; 128(14): 1821-1828, 2016 10 06.
Artigo
Inglês
| MEDLINE | ID: mdl-27531679
17.
Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma.
Blood
; 127(9): 1109-16, 2016 Mar 03.
Artigo
Inglês
| MEDLINE | ID: mdl-26802176
18.
Effects of single-agent bortezomib as post-transplant consolidation therapy on multiple myeloma-related bone disease: a randomized phase II study.
Br J Haematol
; 178(1): 61-71, 2017 07.
Artigo
Inglês
| MEDLINE | ID: mdl-28382618
19.
First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial.
Lancet Oncol
; 17(7): 928-942, 2016 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-27216274
20.
Multiplex polymerase chain reaction-based prognostic models in diffuse large B-cell lymphoma patients treated with R-CHOP.
Br J Haematol
; 174(6): 876-86, 2016 09.
Artigo
Inglês
| MEDLINE | ID: mdl-27196819